Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25432232 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL25371280 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL25371447 | 0.91 | RAD51 (0.44) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL26064225 | 0.86 | MEN1 (0.58) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL26064226 | 0.86 | MEN1 (0.58) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL25432110 | 0.86 | MEN1 (0.58) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL25432658 | 0.84 | RAD51 (0.55) | KDM4EALDH1A1MEN1KMT2ARAD51 | |
| SCHEMBL25432459 | 0.84 | RAD51 (0.45) | KDM4EMEN1KMT2ARAD51GRIN2D | |
| SCHEMBL30590281 | 0.84 | RAD51 (0.45) | KDM4EMEN1KMT2ARAD51GRIN2D | |
| SCHEMBL25430277 | 0.83 | RAD51 (0.41) | KDM4EALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | claimed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | KDM4E 3731/4885ALDH1A1 4307/4885HPGD 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.